AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 12 min read$BBNX

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

Beta Bionics, Inc. (Nasdaq: BBNX) said it will report second-quarter 2026 financial results after market close on July 29, 2026. Management plans a conference call and webcast the same day at 4:30 pm ET to review performance. The webcast link will be posted on the company’s investor site.

Original reporting
manilatimes.net
Published Jul 1, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The only actionable item in the text is the scheduled timing for Q2 2026 results and the associated conference call/webcast.

02

Market read

This functions as an earnings-calendar update for BBNX, setting expectations for potential after-hours volatility on July 29.

03

What to watch

Traders should still watch for any pre-earnings press releases (e.g., guidance changes, payer/coverage updates) that could arrive between now and July 29, which are not mentioned here.

Relevance 4/10Novelty 3/10Timing: ahead of the July 29, 2026 after-hours Q2 results release

Background

Beta Bionics is a commercial-stage diabetes management medical device company; the iLet bionic pancreas is FDA-cleared.

Company-level read

Ticker impact

$BBNXNeutralMedium confidence
Context

Beta Bionics schedules its Q2 2026 financial results for July 29, 2026 after the close, with a 4:30pm ET call/webcast.

Expected impact

Likely modest volatility around the July 29 after-hours release and the 4:30pm ET call, absent any new guidance or datapoints here.

Evidence & confidence

The article discloses only the timing of results and the conference call, not any new financial figures, guidance, or operational updates.

Market effects

Sector

Limited read-across for diabetes device/closed-loop peers because no new clinical, regulatory, or commercial datapoints are provided.

Regional

No specific regional market linkage beyond a single US-listed biotech/med-device name’s earnings calendar.

Global

No global macro or cross-border transaction details; impact is primarily company-specific around earnings.

Counterpoint

What could challenge this read

If BBNX has no material pre-announced catalysts, the earnings-date disclosure may not change expectations much versus what the market already knows.

Key entities

  • company
    Beta Bionics, Inc.

    Nasdaq-listed medical device company announcing its Q2 2026 results date and call time.

Read at source← All news

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min